Blake Borgeson - 31 Oct 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
31 Oct 2023
Net transactions value
-$46,864
Form type
4
Filing time
02 Nov 2023, 19:02:03 UTC
Previous filing
19 Oct 2023
Next filing
16 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $46,864 -8,885 -0.12% $5.27 7,416,305 31 Oct 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $5.21 to $5.35 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.